<DOC>
	<DOC>NCT00534222</DOC>
	<brief_summary>With this observational study we want to examine if the intensity of agitation, the intensity of psychotic symptoms and the presence of sleeping disorder predict the success of the treatment with a atypical antipsychotic after 12 weeks of treatment with patients with a psychotic and/or manic episode. In this study it will be examined what the percentage of patients with a 2-point improvement at the CGI-scale is. Of these group, the responders, retrospective the profile of the responders will be analysed (key-factors and confounders). PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.</brief_summary>
	<brief_title>Unraveling the Relation of Patient's Profile and Therapeutical Effects of Atypicals, Including Quetiapine Effect</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Patients with a manic episode or patients diagnosed with schizophrenia (psychotic episode) Patients who start a treatment with an atypical antipsychotic : quetiapine, olanzapine or risperidone Patients who are prepared to consent to make the coded data available to AstraZeneca Patients with a CGI â‰¥ 4 Patients with a serious underlying disease (including renal or hepatic insufficiency, cancer, cardiovascular diseases and suchlike). Contraindications for quetiapine, olanzapine or risperidone according to the SmPC for these products Patients unable to give informed consent according to the attending physician</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Patients with a manic episode</keyword>
	<keyword>Patients diagnosed w/schizophrenia, who start a treatment with an atypical antipsychotic &amp; who are at least scored as moderately ill on the CGI at baseline</keyword>
</DOC>